CN1536999B - 氟伐他汀钠的晶形 - Google Patents

氟伐他汀钠的晶形 Download PDF

Info

Publication number
CN1536999B
CN1536999B CN028151321A CN02815132A CN1536999B CN 1536999 B CN1536999 B CN 1536999B CN 028151321 A CN028151321 A CN 028151321A CN 02815132 A CN02815132 A CN 02815132A CN 1536999 B CN1536999 B CN 1536999B
Authority
CN
China
Prior art keywords
type
sodium
spit
fluorine
relative humidity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN028151321A
Other languages
English (en)
Chinese (zh)
Other versions
CN1536999A (zh
Inventor
P·A·范德沙亚夫
C·马科利
M·谢拉吉维茨
A·伯克哈德
H·沃勒布
A·沃勒布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Schweiz AG
Original Assignee
Ciba Spezialitaetenchemie Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Spezialitaetenchemie Holding AG filed Critical Ciba Spezialitaetenchemie Holding AG
Publication of CN1536999A publication Critical patent/CN1536999A/zh
Application granted granted Critical
Publication of CN1536999B publication Critical patent/CN1536999B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
CN028151321A 2001-08-03 2002-07-25 氟伐他汀钠的晶形 Expired - Fee Related CN1536999B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01810756 2001-08-03
EP01810756.5 2001-08-03
PCT/EP2002/008276 WO2003013512A2 (en) 2001-08-03 2002-07-25 Crystalline forms of fluvastatin sodium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011103995817A Division CN102516150A (zh) 2001-08-03 2002-07-25 氟伐他汀钠的晶形

Publications (2)

Publication Number Publication Date
CN1536999A CN1536999A (zh) 2004-10-13
CN1536999B true CN1536999B (zh) 2012-08-08

Family

ID=8184071

Family Applications (2)

Application Number Title Priority Date Filing Date
CN028151321A Expired - Fee Related CN1536999B (zh) 2001-08-03 2002-07-25 氟伐他汀钠的晶形
CN2011103995817A Pending CN102516150A (zh) 2001-08-03 2002-07-25 氟伐他汀钠的晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011103995817A Pending CN102516150A (zh) 2001-08-03 2002-07-25 氟伐他汀钠的晶形

Country Status (16)

Country Link
US (1) US6696479B2 (https=)
EP (1) EP1429757B8 (https=)
JP (2) JP4681808B2 (https=)
KR (1) KR100975782B1 (https=)
CN (2) CN1536999B (https=)
AR (1) AR036205A1 (https=)
AT (1) ATE391502T1 (https=)
AU (1) AU2002333271B2 (https=)
CA (1) CA2454072A1 (https=)
DE (1) DE60226044T2 (https=)
ES (1) ES2304140T3 (https=)
HU (1) HUP0401141A3 (https=)
IL (2) IL159861A0 (https=)
PL (1) PL366905A1 (https=)
RU (1) RU2334738C2 (https=)
WO (1) WO2003013512A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
AU2003250086A1 (en) * 2002-07-26 2004-02-23 Ciba Specialty Chemicals Holging Inc. Crystalline polymorphic and amorphous forms of benazepril hydrochloride
WO2004096765A2 (en) * 2003-05-01 2004-11-11 Morepen Laboratories Ltd. A novel crystalline polymorph of fluvastatin sodium and a process for preparing it
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
US7368581B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
JP4037898B2 (ja) * 2003-06-18 2008-01-23 テバ ファーマシューティカル インダストリーズ リミティド フルバスタチンナトリウム結晶形ｘｉｖ、ｌｘｘｉｉｉ、ｌｘｘｉｘ、ｌｘｘｘ及びｘｘｘｖｉｉ型、それらの調製方法、それらを含有する組成物及びそれらの使用方法
US7892354B2 (en) * 2003-10-06 2011-02-22 Solvias Ag Process for the parallel detection of crystalline forms of molecular solids
WO2005037787A1 (en) * 2003-10-16 2005-04-28 Ciba Specialty Chemicals Holding Inc. Crystalline form of fluvastatin sodium
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
WO2005080332A1 (en) * 2004-01-14 2005-09-01 Cadila Healthcare Limited Novel form of fluvastatin sodium
US20070173536A1 (en) * 2004-02-06 2007-07-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
WO2006021967A1 (en) * 2004-08-26 2006-03-02 Biocon Limited Process for the preparation of fluvastatin sodium form a.
WO2006030304A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
WO2006085338A2 (en) * 2005-02-11 2006-08-17 Jubilant Organosys Limited Novel polymorphic forms of fluvastatin sodium and process for preparing the same
WO2006109147A1 (en) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
WO2007039784A2 (en) * 2005-10-06 2007-04-12 Wockhardt Limited A novel crystalline polymorph of fluvastatin sodium and process for preparing it
WO2007054951A1 (en) * 2005-11-14 2007-05-18 Hetero Drugs Limited Process for amorphous esomeprazole
JP2007246522A (ja) * 2006-02-27 2007-09-27 Teva Pharmaceutical Industries Ltd フルバスタチンナトリウムの新規形及びその調製方法
WO2009122425A1 (en) * 2008-04-04 2009-10-08 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
JP6115288B2 (ja) * 2012-04-27 2017-04-19 株式会社島津製作所 質量分析におけるピーク検出方法及びそのシステム
TW201806928A (zh) * 2016-07-01 2018-03-01 第一三共股份有限公司 胺基羧酸之酸加成鹽的結晶及其製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US6124340A (en) * 1996-06-24 2000-09-26 Astra Aktiebolag Polymorphic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500015A (ja) * 1982-11-22 1985-01-10 サンド・アクチエンゲゼルシヤフト メバロラクトン同族体とその誘導体、これらの製造法およびこれらを含有する製薬学的組成物
HU204253B (en) * 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6858643B2 (en) * 2000-10-31 2005-02-22 Ciba Specialty Chemicals Corporation Crystalline forms of Fluvastatin sodium

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US6124340A (en) * 1996-06-24 2000-09-26 Astra Aktiebolag Polymorphic compounds

Also Published As

Publication number Publication date
KR100975782B1 (ko) 2010-08-17
WO2003013512A2 (en) 2003-02-20
IL159861A (en) 2009-02-11
CN102516150A (zh) 2012-06-27
JP4681808B2 (ja) 2011-05-11
DE60226044T2 (de) 2009-05-14
RU2334738C2 (ru) 2008-09-27
AU2002333271B2 (en) 2007-08-09
CN1536999A (zh) 2004-10-13
CA2454072A1 (en) 2003-02-20
PL366905A1 (en) 2005-02-07
HUP0401141A3 (en) 2011-07-28
EP1429757A2 (en) 2004-06-23
JP2010265308A (ja) 2010-11-25
ES2304140T3 (es) 2008-09-16
AR036205A1 (es) 2004-08-18
US20030032666A1 (en) 2003-02-13
RU2004106528A (ru) 2005-07-27
WO2003013512A3 (en) 2003-11-20
US6696479B2 (en) 2004-02-24
IL159861A0 (en) 2004-06-20
EP1429757B1 (en) 2008-04-09
HUP0401141A2 (hu) 2004-09-28
JP2005501838A (ja) 2005-01-20
EP1429757B8 (en) 2008-07-16
ATE391502T1 (de) 2008-04-15
KR20040022226A (ko) 2004-03-11
DE60226044D1 (de) 2008-05-21

Similar Documents

Publication Publication Date Title
CN1536999B (zh) 氟伐他汀钠的晶形
AU593295B2 (en) Paroxetine hydrochloride hemihydrate
AU2002333271A1 (en) Crystalline forms of fluvastatin sodium
US6858643B2 (en) Crystalline forms of Fluvastatin sodium
NO309898B1 (no) Krystallinsk form I [R-(R*,R*)]-2-(4-fluorfenyl)- <beta>,<delta>-dihydroksy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptansyrehemikalsiumsalt
Neau et al. Melting point phase diagrams of free base and hydrochloride salts of bevantolol, pindolol and propranolol
AU2002223639A1 (en) Crystalline forms of fluvastatin sodium
HU227420B1 (en) Produce for resolving of levobupivacaine and its derivates
EP1490333B1 (en) New atorvastatin salts and pharmaceutical compositions containing them
CN1244590C (zh) 嘌呤衍生物核苷酸二钠结晶的制备方法以及除去醇的方法
EP1345903A1 (en) Crystalline forms of cerivastatin sodium
US20030092933A1 (en) Anhydrous crystalline forms of gabapentin
US20050165075A1 (en) Novel amorphous form of valsartan
KR910000652A (ko) (1,2,3,4-테트라하이드로-9-아크리딘이미노) 사이클로헥산 카복실산 및 관련 화합물, 이들의 제조방법 및 약제로서의 용도
US20060241167A1 (en) Crystalline form of fluvastatin sodium
KR910008202B1 (ko) 벤즈아미드 유도체의 제조방법
CN1009928B (zh) 咪唑衍生物的制备方法
US20110275832A1 (en) Process for Preparing Substituted 1,3-dihydro-2H-indol-2-ones
EP0400889B1 (en) Crystalline deoxyspergualin and process for its preparation
JP2004517899A5 (https=)
WO2007039784A2 (en) A novel crystalline polymorph of fluvastatin sodium and process for preparing it
HU189253B (en) Process for preparing 2-pyridyl-alkyl-amine derivatives
TH100977A (th) กระบวนการสำหรับการเตรียม (3-ไซยาโน-1h-อินดอล-7-อิล)[4-(4-ฟลูออโรฟีนีธิล)พิเพอราซิน-1-อิล]เมธาโนนและเกลือของสารนี้

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120808

Termination date: 20140725

EXPY Termination of patent right or utility model